On Friday, Following U.S. Stocks were among the “Top Gainers“: Leggett & Platt, Inc (NYSE:LEG), Alere Inc (NYSE:ALR), Supernus Pharmaceuticals Inc (NASDAQ:SUPN), Nektar Therapeutics (NASDAQ:NKTR)
Leggett & Platt, Inc (NYSE:LEG)’s shares picked up 3.20%, and closed at $45.47, hitting new 52-week high of $45.92. The company has the market capitalization of $6.29B. In the last trading session 2.24M shares changed hands as compared to its average volume of 1.15M shares. The beta value of the stock is 1.13. On the other hand the stock’s volatility for the week is 1.56%, and for the month is 1.35%. The stock price to book value is $5.59, however price to sale value is $1.66. Analyst’s mean recommendation regarding this stock is 3.00. (where 1=Buy, 5=Sale).
Leggett & Platt, Incorporated designs and produces a range of engineered components and products worldwide. The company’s Residential Furnishings segment offers innersprings and wire forms; steel mechanisms and hardware, springs and seat suspensions, steel tubular seat frames, bed frames and ornamental beds, and adjustable beds; and structural fabrics, carpet underlay materials, and geo components. This segment serves manufacturers of finished bedding products and upholstered furniture; retailers and distributors of adjustable and ornamental beds, bed frames, and carpet underlay; and contractors, landscapers, road construction companies, and government agencies using geo components.
Alere Inc (NYSE:ALR), raised 3.18%, and closed at $49.06, hitting new 52-week high of $49.47. The stock has the beta value of 1.91, and its volatility for the week is 2.71%, while for the month it is 2.47%. The company has the market capitalization of $4.14B. The company holds the book value per share of 16.17, whereas cash per share is 4.48. Price to book value is estimated to be 3.03, while price to sale value is 1.60. Analysts mean recommendation for the stock is said to be 2.00 (where 1=Buy, 5=sale).
Alere Inc. provides point-of-care diagnostics and services for infectious and cardiometabolic diseases, and toxicology and in the United States and internationally. It operates in three segments: Professional Diagnostics, Patient Self-Testing, and Consumer Diagnostics. The Professional Diagnostics segment provides diagnostic test products and other in vitro diagnostic tests to medical professionals and laboratories for detection of diseases and conditions in the areas of viral hepatitis; respiratory syncytial virus; influenza; pneumonia; tuberculosis; human immunodeficiency virus/attaind immunodeficiency syndrome; gastrointestinal disease; vector-borne diseases, such as malaria and dengue; and herpes and other sexually-transmitted diseases, in addition to diabetes, high blood pressure, high cholesterol, metabolic syndrome, coronary artery disease, heart attack, and heart failure and stroke.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN), enhanced 3.16%, and closed at $11.77, hitting new 52-week high of $11.83. The company holds the market capitalization of 518.93M. For the trailing twelve months, the stock’s return on equity value remains -16.80%, while return on assets value is -6.30%, in response to its return on investment value of -105.30%. Its 20-day moving average gained 25.86%, above 50-day moving average of 32.51%, above 200-day moving average of 32.15% from the latest market price of $ 11.77. The mean recommendation of analysts for this stock is 2.20.(where 1=Buy, 5=Sale).
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products comprise Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has accomplished Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has accomplished Phase IIa clinical trials for the treatment of ADHD.
Nektar Therapeutics (NASDAQ:NKTR), rose 2.97%, and closed at $13.89. The stock has price to sale value of 9.09, however, price to book value is 49.61. With recent incline, the year-to-date (YTD) performance reflected a -10.39% decline below last year. During the past month the stocks gain 4.51%, bringing three-month performance to -11.08% and six-month performance to 0.51%. The mean recommendation of analysts for this stock is 1.80. (where 1=Buy, 5=Sale).
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. The company offers MOVANTIK, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives. Its drug candidates in clinical development stage comprises BAX 855 that is in Phase III clinical trial for treating Hemophilia A; BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181 that is in Phase III clinical trial for chronic pain; NKTR-171, which is in Phase I clinical trial to treat neuropathic pain; and NKTR-214 that is in research and preclinical trial stage to treat oncology, in addition to MOVANTIK, which is research and preclinical stage for treating chronic pain without constipation.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
